spacer
home > ebr > summer 2003 > preclinical juvenile toxicity studies: will it be safe for children?
PUBLICATIONS
European Biopharmaceutical Review

Preclinical Juvenile Toxicity Studies: Will it be Safe for Children?

The last issue of EPC highlighted the growth in paediatric clinical trials and difficulties in performing studies in children. Similar gaps in study cover have become an issue in preclinical studies and it is only in recent years that any studies have focused on the potential effects of direct treatment of young animals and on possible long-term effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences

Audrey Bottomley is a UK Registered Toxicologist and the Principal Consultant Toxicologist to the Reproductive Studies Group with over 30 years' experience in reproductive and developmental toxicology. She is now primarily concerned with advising external clients and Huntingdon Life Sciences staff on the design and interpretation of reproductive studies.


David Myers is a Senior Study Director and Consultant Toxicologist within the Reproductive Studies Group. He has a PhD in age-related changes in the behaviour and brain of the ageing female mouse and is a specialist in the effects of treatments on behaviour in rodents. David is directly involved with study design management and interpretation in the developing field of behavioural testing.


Chris Willoughby is Head of the Reproductive Studies Group at Huntingdon Life Sciences and has qualifications in pharmacy and toxicology. He has worked in reproductive toxicology with Huntingdon Life Sciences since 1974 and has extensive experience managing studies of all types.

spacer
Chris Willoughby
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019

Experts from IKEA, the British Plastics Federation and The Sunday Times to create a forum for education, knowledge-sharing and debate
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement